AbbVie Inc (NASDAQ:ABBV)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Credit Suisse in a note issued to investors on Monday, Market Beat reports.

ABBV has been the topic of a number of other reports. Jefferies Group dropped their price target on shares of AbbVie from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Thursday, January 14th. Vetr raised shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $68.33 price target on the stock in a research report on Thursday, December 10th. Citigroup Inc. reissued a “neutral” rating and set a $56.00 price target (down from $60.00) on shares of AbbVie in a research report on Saturday, October 24th. Zacks Investment Research downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a report on Monday, January 4th. Finally, Cowen and Company restated an “outperform” rating and set a $70.00 price objective (down previously from $75.00) on shares of AbbVie in a report on Thursday, December 3rd. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. AbbVie currently has an average rating of “Buy” and a consensus target price of $71.66.

AbbVie (NASDAQ:ABBV) traded down 0.31% during mid-day trading on Monday, reaching $58.65. 9,566,921 shares of the company’s stock were exchanged. The company has a 50-day moving average of $56.73 and a 200-day moving average of $60.67. AbbVie has a 52-week low of $45.45 and a 52-week high of $71.60. The stock has a market cap of $95.88 billion and a price-to-earnings ratio of 34.02.

AbbVie (NASDAQ:ABBV) last released its quarterly earnings results on Friday, October 30th. The company reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. The firm had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $5.90 billion. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.89 earnings per share. Equities research analysts anticipate that AbbVie will post $4.29 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $0.57 per share. The ex-dividend date is Wednesday, January 13th. This is a boost from AbbVie’s previous quarterly dividend of $0.51. This represents a $2.28 annualized dividend and a yield of 3.89%.

Other large investors recently made changes to their positions in the company. Beacon Capital Management raised its stake in shares of AbbVie by 150.0% in the fourth quarter. Beacon Capital Management now owns 5 shares of the company’s stock valued at $0 after buying an additional 3 shares during the last quarter. Water Island Capital bought a new stake in shares of AbbVie during the third quarter valued at about $27,000. Vicus Capital bought a new stake in shares of AbbVie during the fourth quarter valued at about $258,000. Central Bank & Trust Company raised its stake in shares of AbbVie by 1.2% in the fourth quarter. Central Bank & Trust Company now owns 4,596 shares of the company’s stock valued at $272,000 after buying an additional 54 shares during the last quarter. Finally, vontobel swiss wealth advisors AG bought a new stake in shares of AbbVie during the fourth quarter valued at about $273,000.

AbbVie Inc. (NASDAQ:ABBV) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

12 Month Chart for NASDAQ:ABBV

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.